SubHero Banner

Lumoxiti (moxetumomab pasudotox-tdfk) – New orphan drug approval

September 13, 2018 - The FDA announced the approval of AstraZeneca's Lumoxiti (moxetumomab pasudotox-tdfk), for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Download PDF